Nature Communications (Sep 2019)
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
- S. Rahima Benhabbour,
- Martina Kovarova,
- Clinton Jones,
- Daijha J. Copeland,
- Roopali Shrivastava,
- Michael D. Swanson,
- Craig Sykes,
- Phong T. Ho,
- Mackenzie L. Cottrell,
- Anush Sridharan,
- Samantha M. Fix,
- Orrin Thayer,
- Julie M. Long,
- Daria J. Hazuda,
- Paul A. Dayton,
- Russell J. Mumper,
- Angela D. M. Kashuba,
- J. Victor Garcia
Affiliations
- S. Rahima Benhabbour
- UNC_NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill
- Martina Kovarova
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Clinton Jones
- UNC Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
- Daijha J. Copeland
- UNC Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
- Roopali Shrivastava
- UNC_NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill
- Michael D. Swanson
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Craig Sykes
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
- Phong T. Ho
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Mackenzie L. Cottrell
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Anush Sridharan
- UNC_NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill
- Samantha M. Fix
- UNC Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
- Orrin Thayer
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Julie M. Long
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- Daria J. Hazuda
- Infectious Disease Biology, Merck Research Laboratories
- Paul A. Dayton
- UNC_NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill
- Russell J. Mumper
- University of Georgia, Office of the Provost
- Angela D. M. Kashuba
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
- J. Victor Garcia
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for Aids Research, School of Medicine, University of North Carolina at Chapel Hill
- DOI
- https://doi.org/10.1038/s41467-019-12141-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
Patient drug regime compliance is a major issue; sustained release implants could address this. Here, the authors report on a phase inverted in situ forming implant of PLGA for the sustained release of antiretroviral drugs and optimize and demonstrate the release of 6 different drugs over a period of up to a year.
